Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), has announced it entered into a combined term loan and product royalty financing agreement with Barings that has allowed Coherus to fully pay off the remaining US$75 million of its Pharmakon Advisors term loan. Under the terms of the royalty monetization facility, Coherus received US$37.5 million in return for a certain net sales royalty percentage consideration on US sales of LOQTORZI® and UDENYCA® up to a hard cap. Under the term loan, Coherus received US$38.7 million in proceeds from a structured debt loan with a May 2029 maturity. Latham & Watkins LLP represented Coherus in the transaction with a corporate deal team led by Bay Area partners Jekkie Kim, Dan Van Fleet, Ben Potter, and Phillip Stoup, with associates Mizuna Sekine, Trevor Church, Patrick Chew, and Rychelle Andersen. Advice was also provided on tax matters by partners Eric Cho and Katharine Moir, with associates Sam Yang and Rasha Suleiman; on security matters by counsel Emily Yu; on healthcare regulatory matters by Washington, D.C. counsel Chad Jennings; and on convertible debt related matters by Los Angeles/New York partner Greg Rodgers.~~